Riskpilot← Back to searchSign inGet full accessEndonova AB
ABActiveOrg 5568015258Orrekulla Industrigata 11Wholesale of pharmaceutical and medical goods · NACE 4646Est. 20102 employees
Revenue 2025
SEK 21,9M
+27% vs 2024
EBITDA margin
10.1%
+30% vs 2024
Equity ratio
42.2%
Financial strength
Net profit 2025
SEK 1,3M
+43% vs 2024
| Revenue | SEK 21,9M | +27% |
| EBITDA | SEK 2,2M | +30% |
| Net profit | SEK 1,3M | +43% |
| Total assets | SEK 7,6M | +24% |
| Equity | SEK 3,2M | +27% |
| Employees | 2 | — |
Legal name
Endonova AB
Org number
5568015258
Legal form
Aktiebolag
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
1 mars 2010
Share capital
SEK 100 000
Employees
2 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2025-08-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas var för sig av ledamöterna suppleanten
Company purpose
Bolaget skall köpa och importera begagnad samt ny medicinteknisk utrustning och instrument för att sälja vidare till veterinär- mottagningar och humana privatkliniker jämte därmed förenlig verksamhet.
Address
Orrekulla Industrigata 11
Phone
+4631685000
Email
anders.ericsson@endonova.se
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 10 847 | 12 411 | 13 196 | 17 187 | 21 865 |
| Staff expenses | — | — | −1 797 | −1 924 | −2 136 |
| EBITDA | 1 249 | 1 639 | 1 610 | 1 689 | 2 203 |
| Depreciation & amort. | −50 | −57 | −61 | −61 | −28 |
| EBIT | 1 199 | 1 582 | 1 549 | 1 628 | 2 175 |
| Net financials | −47 | −46 | −90 | −40 | −19 |
| Profit before tax | 903 | 1 571 | 1 159 | 1 173 | 1 681 |
| Tax | −198 | −332 | −246 | −257 | −368 |
| Net profit | 705 | 1 239 | 913 | 916 | 1 314 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 4 159 | 4 233 | 4 220 | 6 099 | 7 557 |
| Equity | 1 988 | 2 477 | 2 289 | 2 505 | 3 189 |
| Long-term debt | 0 | 0 | — | — | — |
| Short-term debt | 1 421 | 1 041 | 915 | 2 164 | 2 463 |
| Total debt | 1 421 | 1 041 | 915 | 2 164 | 2 463 |
EBITDA margin
10.1%
This company
15.8%
Market median
-36% vs market
20212025
Equity ratio
42.2%
This company
38.2%
Market median
+10% vs market
20212025
Return on equity
41.2%
This company
18.4%
Market median
+124% vs market
20212025
Net profit margin
6.0%
This company
8.1%
Market median
-26% vs market
20212025
Asset turnover
2.89×
This company
1.12×
Market median
+158% vs market
20212025
Debt / equity
1.37×
This company
0.62×
Market median
-121% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2024-09-01 – 2025-08-31
- Annual report 2024Filed via Bolagsverket / SCB · Period 2023-09-01 – 2024-08-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2022-09-01 – 2023-08-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2021-09-01 – 2022-08-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2020-09-01 – 2021-08-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
EG Chief Auditor | Chief Auditor | 2025 |
| Former (1) | ||
EH | Audit | 2022 – 2025 |
| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
| Deputy Board Member | 2022 | |
| Board of Directors | 2022 | |
| Chairman | 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Endonova AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Ewelynne Helen Elonsson | Audit | 0 companies |
| Erik Gunnar Hansson | Chief Auditor | 0 companies |
| Bengt Olof Anders Ericsson | Deputy Board Member | 0 companies |
| Anders Olof Ericsson | Board of Directors | 0 companies |
| Leif Thomas Gisslén | Chairman | 0 companies |